Why Streaming in Spanish may be a Growing Market For Businesses

With 500 million native Spanish speakers worldwide we are seeing incredible growth in Spanish content delivery through streaming. On today’s video stream, Mrugesh Desai, Lead, North American Region for Accedo joins host Daniel Litwin to discuss how this market is evolving.

While major streaming services such as Netflix and Hulu provide some Spanish content, there is a growing market for exclusive streaming. The largest Spanish-language content production house, the newly merged Televisa-Univision will be launching a Spanish-language streaming service for US, Mexican, and broader Spanish-speaking markets.

“There’s a large enough audience. And lots of nuances is the demographics for these services to coexist and expand together with more Spanish language content” Desai said. Currently, much of that content focuses on local news and a local audience but there is demand for a wider menu of content. “If you’re to get broader appeal among the younger generation,’ Desai continued, “perhaps having some of the “niche” content services may mean the difference between customers subscribing and not subscribing.”

Accedo focuses on user experience in developing UI and UX that is specifically tailored to regions and demographics. As Desai said, “We’ve learned over time working with our Spanish language streaming customers the UI expectations for a Hispanic audience are quite different” For OTT streaming services, Accedo looks at the usage patterns of demographics to determine the best mediums and devices for content whether it’s web, mobile, smart TVs, or gaming consoles. Defining the right UX paradigm gives the audience a seamless path to finding the content they want. Accedo can help strategize how to approach this from the standpoint of the global expansion of Spanish language streaming services. For more information go to www.accedo.tv

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

 

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More